Healthcare & Pharmaceutical Market Research in China

BioNixus is a leading healthcare market research company in China, delivering HCP surveys at Tier 3A (三甲) hospitals, NHSA NRDL payer research, VBP procurement intelligence, and KOL mapping aligned with NMPA and NHSA requirements. BioNixus combines primary research depth with physician access across major Chinese academic medical centres and Tier 3A hospital networks across 34 provinces.

A healthcare market research company in China designs and executes studies covering physician prescribing behaviour at Tier 3A hospitals, NHSA NRDL annual negotiation payer dynamics, VBP (Volume-Based Procurement / 集中带量采购) procurement impact, provincial PRLS supplementary formulary access, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Chinese market.

China operates a complex, multi-layered healthcare system under NHSA national administration managing reimbursement for over 1.4 billion people. NMPA approval does not guarantee market access — commercial outcomes depend on NHSA NRDL annual negotiation, VBP (Volume-Based Procurement / 集中带量采购) centralized tendering that has driven 50–90%+ price cuts since 2019, provincial PRLS supplementary listing across 34 provinces, and individual Tier 3A hospital formulary committee approval. No other major market combines this annual payer negotiation cycle, VBP price-reset dynamics, and hospital-level formulary access barrier in a single commercial landscape.

BioNixus covers oncology and haematology (CSCO-aligned, IO combinations, biosimilar VBP dynamics), cardiovascular (SGLT2, PCSK9, HFrEF NRDL dynamics), diabetes and metabolic (GLP-1, insulin VBP impact), rare disease (NMPA orphan drug pathways, NHSA NRDL rare disease negotiations), immunology and biologics (VBP biosimilar price cut research, biologic step therapy), medical devices (NMPA device registration, DRG-driven adoption), and consumer health across the Chinese market.

Yes. BioNixus maintains physician and specialist networks across China's leading Tier 3A (三甲) academic medical centres including Peking Union Medical College Hospital (PUMCH), West China Hospital Chengdu, Zhongshan Hospital Shanghai, Ruijin Hospital, and PLA General Hospital. For specialty and rare disease areas, we recruit through CSCO (Chinese Society of Clinical Oncology), CSH (Chinese Society of Hematology), CCS (Chinese Society of Cardiology), and national specialty society networks, with coverage across all 34 provinces, autonomous regions, and direct-controlled municipalities.

Focused HCP surveys at Tier 3A hospitals typically complete in 3–5 weeks. Full mixed-method programmes including NHSA payer depth interviews and VBP impact modules typically run 6–10 weeks depending on therapy area and respondent scarcity. Oncology KOL programmes with multi-city recruitment across Beijing, Shanghai, Guangdong, and Sichuan may require extended planning timelines for high-value specialist recruitment.

Yes. BioNixus designs and executes Chinese patient research in compliance with China's Personal Information Protection Law (PIPL) requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling aligned with PIPL data localisation and cross-border transfer requirements.

Yes. Chinese modules can run with comparable cells in Japan, South Korea, Singapore, Australia, and global markets — using consistent instruments. This enables global portfolio committees managing Asia-Pacific launch sequencing and NHSA-to-PMDA-to-HIRA payer benchmarking from one research partner.